0000899243-23-016481.txt : 20230626
0000899243-23-016481.hdr.sgml : 20230626
20230626160521
ACCESSION NUMBER: 0000899243-23-016481
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230626
FILED AS OF DATE: 20230626
DATE AS OF CHANGE: 20230626
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Parkinson David Ross
CENTRAL INDEX KEY: 0001451935
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-28386
FILM NUMBER: 231042366
MAIL ADDRESS:
STREET 1: C/O THRESHOLD PHARMACEUTICALS, INC.
STREET 2: 170 HARBOR WAY SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CTI BIOPHARMA CORP
CENTRAL INDEX KEY: 0000891293
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 911533912
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 800
CITY: SEATTLE
STATE: WA
ZIP: 98121
BUSINESS PHONE: 2062827100
MAIL ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 800
CITY: SEATTLE
STATE: WA
ZIP: 98121
FORMER COMPANY:
FORMER CONFORMED NAME: CELL THERAPEUTICS INC
DATE OF NAME CHANGE: 19960321
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-26
1
0000891293
CTI BIOPHARMA CORP
CTIC
0001451935
Parkinson David Ross
3101 WESTERN AVENUE, SUITE 800
SEATTLE
WA
98121
1
0
0
0
0
Stock Option (Right to Buy)
4.07
2023-06-26
4
D
0
50000
D
Common Stock
50000
0
D
Stock Option (Right to Buy)
4.61
2023-06-26
4
D
0
60000
D
Common Stock
60000
0
D
Stock Option (Right to Buy)
0.8411
2023-06-26
4
D
0
120000
D
Common Stock
120000
0
D
Stock Option (Right to Buy)
1.00
2023-06-26
4
D
0
126000
D
Common Stock
126000
0
D
Stock Option (Right to Buy)
3.30
2023-06-26
4
D
0
80000
D
Common Stock
80000
0
D
Stock Option (Right to Buy)
4.49
2023-06-26
4
D
0
80000
D
Common Stock
80000
0
D
Stock Option (Right to Buy)
4.08
2023-06-26
4
D
0
80000
D
Common Stock
80000
0
D
Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)
(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.
/s/ Adam R. Craig, attorney-in-fact for David Ross Parkinson
2023-06-26